Focus Area Neuroscience
Solutions Strategy Consulting

The client

An emerging biotech company is engineering a class of next-generation biologics that target and prolong pro-survival signaling of apoptotic cells.

Challenge

The client had previously explored next-generation biologics in other acute injuries but was now interested in investigating acute neuronal injuries such as stroke and traumatic brain injury (TBI). The client needed to understand the opportunity of their technology and pipeline with an emphasis on stroke, including high-level perspectives around TBI translated into a US forecast model, conveying potential long-term revenue.

Approach

We investigated current treatments, unmet needs, new therapy development history, competitive landscape, and market trends to understand complex implications for the stroke and TBI space.

Our team conducted in-depth interviews with physicians specializing in stroke and TBI to refine preclinical and clinical development considerations and a product value proposition.

We then simulated a range of market scenarios and integrated assumptions supported by research learnings to develop a revenue forecast and potential barriers and solutions to barriers to achieve peak revenue.

Valued outcome

Provided healthcare practitioner (HCP)-based insights on key development considerations including preclinical experiments and target patient segments to streamline clinical development
Assessed opportunities and challenges across multiple patient subpopulations with clear prioritization to maximize market share
Developed expert-informed US revenue forecast, including key assumptions, sensitivities, and scenarios, as well as a high-level revenue perspective across secondary indications and geographies to assess the opportunity with implications for the commercialization strategy